Marshall Wace, LLP Praxis Precision Medicines, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $545,202 - $1.07 Million	626,669 New	626,669 $1.07 Million
Q1 2023 May 15, 2023	BUY	$0.8 - $4.98 $226,956 - $1.41 Million	283,695 New	283,695 $229,000
Q1 2022 May 16, 2022	SELL	$10.21 - $20.29 $164,248 - $326,405	-16,087 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$16.76 - $22.99 $3.1 Million - $4.26 Million	-185,224 Reduced 92.01%	16,087 $316,000
Q3 2021 Nov 15, 2021	BUY	$13.15 - $22.56 $164,046 - $281,436	12,475 Added 6.61%	201,311 $3.72 Million
Q2 2021 Aug 13, 2021	BUY	$18.28 - $33.05 $3.45 Million - $6.24 Million	188,836 New	188,836 $3.45 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.